Cargando…
EphA2 Is a Clinically Relevant Target for Breast Cancer Bone Metastatic Disease
EphA2 receptor tyrosine kinase (RTK) is highly expressed in breast tumor cells across multiple molecular subtypes and correlates with poor patient prognosis. In this study, the potential role of EphA2 in this clinically relevant phenomenon is investigated as metastasis of breast cancer to bone is a...
Autores principales: | Vaught, David B, Merkel, Alyssa R, Lynch, Conor C, Edwards, James, Tantawy, Mohammed Noor, Hilliard, Timothy, Wang, Shan, Peterson, Todd, Johnson, Rachelle W, Sterling, Julie A, Brantley‐Sieders, Dana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046157/ https://www.ncbi.nlm.nih.gov/pubmed/33869989 http://dx.doi.org/10.1002/jbm4.10465 |
Ejemplares similares
-
Oncogenic Functions and Therapeutic Targeting of EphA2 in Cancer
por: Wilson, Kalin, et al.
Publicado: (2021) -
Eph receptors in breast cancer: roles in tumor promotion and tumor suppression
por: Vaught, David, et al.
Publicado: (2008) -
Targeting EphA2 impairs cell cycle progression and growth of basal-like/triple-negative breast cancers
por: Song, W, et al.
Publicado: (2017) -
EphA5 and EphA6: regulation of neuronal and spine morphology
por: Das, Gitanjali, et al.
Publicado: (2016) -
Ephrin Receptors (Eph): EphA1, EphA5, and EphA7 Expression in Uveal Melanoma—Associations with Clinical Parameters and Patient Survival
por: Gajdzis, Malgorzata, et al.
Publicado: (2020)